Tumor marker
A tumor marker, cancer technology, applied in the field of tumor markers
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0054] Research purposes
[0055] Through the following three aspects of the test content, evaluate the clinical use and clinical performance of the Hsp90α quantitative detection kit.
[0056] 1. Measure the Hsp90α content in the plasma of healthy people, patients with lung cancer, patients with non-cancerous lesions of the lung, and patients with other malignant tumors, test the clinical accuracy, specificity and sensitivity of the Hsp90α kit detection, and use the ROC curve to determine the appropriateness Positive reference value (cut-off value);
[0057] 2. Perform dynamic monitoring of the Hsp90α content in the plasma of lung cancer patients during the treatment period to test the correlation between the concentration changes and the changes in the patient's condition, that is, the clinical effectiveness of the efficacy monitoring;
[0058] 3. To compare the test results of Hsp90α with carcinoembryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) respective...
Embodiment 2
[0087] 2. Summary of main results
[0088] 2.1 Non-dynamic monitoring group
[0089] A total of 2036 cases were enrolled in the non-dynamic monitoring group of this study (lung cancer patient group: 1046 cases, other malignant tumor group: 37 cases, lung non-cancerous lesion group: 344 cases, lung benign tumor group: 17 cases, healthy people Group: 592 cases), of which 2036 cases were in line with the protocol, and no subjects were excluded. For details, refer to Table 8.1.1.1-Table 8.1.1.2. The distribution of cases in each center is shown in Table 8.1.1.3.
[0090] Hsp90α diagnostic performance evaluation
[0091] In order to evaluate the performance of Hsp90α in diagnosing lung cancer and non-cancerous tumors, a total of 1999 cases were excluded from the analysis, including 1,046 cases in the lung cancer group and 953 cases in the non-cancer group. The demographic information of the two groups of subjects and the basic diagnosis classification of the lung cancer group are shown ...
Embodiment 3
[0110] 3. Statistical analysis results
[0111] 3.1 Non-dynamic detection group
[0112] Table 8.1.1.1 Enrolled subjects and analysis data set
[0113]
[0114] Table 8.1.1.2 Case distribution of non-dynamic subjects
[0115]
[0116] 3.1.1 Lung cancer group and non-cancer group
[0117] 3.1.1.1 Hsp90α diagnostic performance evaluation
[0118] 3.1.1.1.1 Subject characteristics
[0119] Table 8.1.1.1.1.1 Demographic information of all subjects
[0120]
[0121] Table 8.1.1.1.1.2 Diagnosis of lung cancer subjects
[0122]
[0123] 3.1.1.1.2 Evaluation of Hsp90α diagnostic performance (lung cancer group and non-cancer group)
[0124] Table 8.1.1.1.2.1 Hsp90α test results of the two groups of subjects
[0125]
[0126] figure 1 It is the ROC curve of Hsp90α test results (based on all subjects who tested Hsp90α).
[0127] Table 8.1.1.1.2.2 Four grid table judged according to the cut-off value of Hsp90α detection result
[0128]
[0129] Table 8.1.1.1.2.3 Diagnosis results judged based on the cut-of...
PUM
| Property | Measurement | Unit |
|---|---|---|
| Sensitivity | aaaaa | aaaaa |
| Sensitivity | aaaaa | aaaaa |
| Sensitivity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More